Explorative study compares two fast-acting interventions for treating adults with treatment-resistant depression, suggesting new options.
Treatment-resistant depression (TRD), the non-response to two different antidepressant classes during a major depressive episode, is a severe clinical condition in almost 30% of depressed patients, carrying substantial direct and indirect financial burdens on the healthcare system [1]. Accelerated ArTMS (arTMS) protocols are novel approaches that exert a comparable antidepressant efficacy without significantly compromising the safety and tolerability associated with the standard rTMS regimen [2,3].
No takes yet. Share an insight, caveat, or question.
Pettorruso et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: